Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers presented a case study on Exo.Reset®, a cosmetic formulation using extracellular vesicle technology, demonstrating systematic application of recognized standards to ensure scientific rigor and regulatory compliance in skin rejuvenation product development, providing a practical model for EV-based cosmetic innovations.

In this study, compliance with UV protection recommendations was highest among vitiligo patients compared to those with other cutaneous immune-mediated inflammatory dermatoses, indicating a need for tailored education to improve compliance across all groups.

In this case report, isotretinoin treatment led to complete remission of folliculitis decalvans lesions in a 26-year-old male after a year and a half, despite the lack of certain histopathology images and control tests; the findings also suggest potential familial clustering needing further genetic investigation.

This study found that scalp cooling effectively reduces chemotherapy-induced hair loss, especially with taxane-based regimens, and recent U.S. trials support its safety, despite logistical and insurance challenges.

In this study, topical eflornithine reduced hair regrowth in hirsute patients following intense pulsed light therapy, suggesting it may maintain IPL-induced hair reduction over six months.

This qualitative study revealed that women with PCOS often see themselves as less feminine, affected by symptoms like excess hair and irregular menstruation, which challenged their gender roles.

This study demonstrated that intradermal treatment with a medical device using Polynucleotides High Purification Technology (PN HPT) significantly improved skin surface, firmness, pigmentation, and radiance in 30 Asian subjects, with benefits lasting up to six months and no adverse events reported.

This study found that the combination of zinc sulfate and calcium pantothenate improved hair density and participant satisfaction in women with hair loss, suggesting its potential as an initial treatment option.

This paper discusses the introduction and advantages of an Insurance-Based Billing Model for scalp cooling devices in the USA, which can enhance access to this treatment for reducing chemotherapy-induced alopecia, particularly benefiting underserved and disadvantaged populations.

This case series reports on five cats who experienced moderate to severe skin reactions after receiving the frunevetmab injection, noting pruritus, alopecia, and ulcerations developing within days of treatment.

In this study, the Swedish Hairdex-S was well-received by alopecia areata patients and demonstrated strong psychometric properties and consistency with the original version, supporting its use for patient quality of life evaluation and research.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.

This study found that people taking Serenoa repens for more than 14 days had a higher likelihood of serious adverse reactions, particularly when also using multiple or interacting supplements, although higher SR doses were linked to lower risk.

In this study, 5-aminolevulinic acid photodynamic therapy did not improve hair growth in patients with androgenetic alopecia but was safe and slightly reduced scalp sebum secretion.

In this randomized trial of Iranian men with moderate to severe androgenetic alopecia, researchers found that both finasteride and dutasteride improved hair density over 24 weeks, with dutasteride showing stronger PSA reduction but similar safety to finasteride.

This case report describes an 85-year-old woman who developed localized telogen effluvium, a form of temporary hair loss, three months after Mohs micrographic surgery for basal cell carcinoma on her scalp, with complete hair regrowth achieved through minoxidil therapy within ten months.

This study found that treating moderate-to-severe prurigo nodularis with dupilumab significantly improved itch severity, skin condition, and quality of life over 104 weeks, with a favorable safety profile, even in elderly and comorbid patients.

In this study, 80% of pediatric patients with alopecia areata treated with calcipotriol/betamethasone ointment showed hair regrowth over 12 weeks, suggesting it may be an effective option, though 20% had no improvement or worsening symptoms.

In this study, women with acute telogen effluvium taking the Hair’InsideTM supplement for 84 days showed significant improvements in hair regrowth, shedding, brightness, and volume compared to placebo, with no reported adverse effects.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

In this study, Pilopeptan® Intensive, a nutritional supplement containing hydrolyzed collagen, Group B vitamins, and zinc, was found to significantly improve hair parameters in telogen effluvium patients, with sustained benefits observed posttreatment, although mild side effects were reported by some participants.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.

This case series suggests that a nutraceutical gummy may effectively promote hair regrowth and reduce hair shedding in women with female pattern hair loss and telogen effluvium.

This study observed that autologous growth factor concentrate combined with topical minoxidil significantly improved hair growth and patient satisfaction in individuals with androgenic alopecia, with no adverse effects reported.

This study found that topical cetirizine increased hair shaft thickness and improved clinical outcomes from the patients' perspective in female androgenetic alopecia compared to minoxidil alone, with similar side effect profiles.

This review discusses male androgenetic alopecia treatments, noting that topical minoxidil and oral finasteride are FDA-approved and require continuous use to maintain hair retention effects, but reports no new clinical results.

This review discusses recent evidence on how night-shift work affects the circadian system, sleep, and alertness in shift workers, and reports no clinical results; potential impacts on health are considered.

This review discusses the unique advantages and challenges of microneedle arrays for vaccine and immunotherapy delivery but reports no new clinical results.

This article outlines how nanotechnology strategies, including phospholipid-based nanocarriers like liposomes, could enhance the effectiveness and skin tolerability of acne treatments, aiming to reduce side effects and improve patient compliance in managing acne vulgaris.